

Tepotinib

Adjudication Guideline

Rule Category:
Pharmaceutical

Ref: No:
2023-PH-29

Version Control:
Version No. V1.0

Effective Date:
25th August 2023

Last Update:
19th October 2024

Approved by:
Daman

Responsible:
Pharmacy Standards
& Governance

**Related Adjudication
Guidelines:** N/A

Table of Contents

1.	Abstract	3
1.1	For Members.....	3
1.2	For Medical Professionals.....	3
2.	Scope	3
3.	Adjudication Policy.....	3
3.1	Eligibility / Coverage Criteria.....	3
3.2	Requirements for Coverage	4
3.3	Non-Coverage.....	4
3.4	Payment and Coding Rules	4
4.	Denial Codes.....	4
5.	Appendices	5
5.1	References	5
5.2	Revision History	5

1. Abstract

1.1 For Members

Tepotinib is an oral medication used for the treatment of advanced metastatic lung cancer. This drug is administered as an oral tablet. Before receiving Tepotinib, the patient is required to discuss with the healthcare provider about existing medical conditions. Your clinician should also know about the history of pregnancy, liver and lung function status prior to undergoing therapy with this drug.

1.2 For Medical Professionals

Tepotinib is a kinase inhibitor and approved by FDA for the treatment of adult patients with METex14 exon skipping variation advanced metastatic non-small cell lung carcinoma. Tepotinib is currently not indicated for paediatric patients. The medication is given orally. This medication may increase the risk of Interstitial lung disease and hepatotoxicity, and thus liver function and lung function are to be assessed in these patients. Some patients may experience some serious adverse effect upon drug administration, and it is highly recommended to be prescribed by trained and experienced health care professionals specializing in oncological treatment.

2. Scope

The scope of this adjudication rule is to highlight the coverage and payment for Tepotinib for all DAMAN-managed health insurance plans, subject to policy terms and condition.

3. Adjudication Policy

3.1 Eligibility / Coverage Criteria

Tepotinib is considered medically necessary for the treatment of advanced metastatic non-small cell lung cancer (NSCLC) when below criteria meet:

- 18 years of age or older.
- Documented diagnosis of Advanced metastatic NSCLC (non-small cell lung carcinoma) with METex14 mutation.

Tepotinib Dose and administration:

- 450 mg orally once daily with food until disease progression or unacceptable toxicity.

Tepotinib Dose Table:

Tepotinib Dose	Methods of administration
Oral 450 mg once daily.	Oral Tablets

3.2 Requirements for Coverage

- ICD and CPT / Drug codes must be coded to the highest level of specificity.
- Treatment should be initiated when the below requirements are met:
 - Documented evidence of METex14 skipping mutation with advanced metastatic lung cancer confirmed on histopathology/radiology report.
 - No evidence of Interstitial Lung Disease/Pneumonitis prior to initiation or during therapy.
 - Negative pregnancy status.
 - Liver Function within normal limits.

Eligible clinician Specialities:

Eligible clinician specialities
Medical Oncology
Radiation Oncology
Surgical Oncology

Questionnaire link:

<https://www.damanhealth.ae/main/pdf/support/Questionnaire/Pre%20approval%20Form%20for%20Tepotinib.pdf>

3.3 Non-Coverage

Tepotinib is not covered for visitor plan Administered by Daman.

3.4 Payment and Coding Rules

Please apply DOH payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

4. Denial Codes

Code	Code Description
MNEC-004	Service is not medically indicated.
AUTH-001	Pre-approval was not acquired for rendered services.
CODE-010	Prescribing clinician is eligible for this service.
CODE-014	Activity/diagnosis is inconsistent with the patient's age/gender

5. Appendices

<https://www.damanhealth.ae/main/pdf/support/Questionnaire/Pre%20approval%20Form%20for%20Tepotinib.pdf>

5.1 References

https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf

<https://www.nice.org.uk/guidance/TA789/chapter/1-Recommendations>

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214096s001s002lbl.pdf

5.2 Revision History

Date	Version No.	Change(s)
25/8/2023	V1.0	Release of V1.0
19/10/2024	V2.0	No changes / Release of V2.0

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.